Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares are trading higher in Monday’s after-hours session after the company scheduled a Phase 3 trial results readout for this week.

• Amylyx Pharmaceuticals shares are testing new highs. What’s driving AMLX to record levels?

Amylyx Pharma Announces Phase 3 LUCIDITY Results Date

Amylyx Pharmaceuticals said it will announce the top-line results for its Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) Tuesday morning. Senior management will hold a conference call at 8 a.m. ET to discuss results from the trial.

Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with FDA Breakthrough Therapy Designation in PBH.

The trial enrolled 78 participants over 16 weeks as a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery.

The last participant was randomized and dosed in the Phase 3 clinical trial in March. If approved, commercial launch of avexitide is anticipated in 2027.

AMLX Shares Surge After the Close

AMLX Price Action: Amylyx shares were up 15.73% in after-hours Monday, trading at $24.80 at the time of publication, according to Benzinga Pro.

Image: Shutterstock.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.